O-GlcNAc Transferase: A Key Enzyme in Protein Biosynthesis and Cellular Processes

Target Name: UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase)

NCBI ID: P31223

UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase)

Other Name(s): (O-GlcNAc Transferase | O-linked N-acetylglucosamine transferase | OGT

O-GlcNAc Transferase: A Key Enzyme in Protein Biosynthesis and Cellular Processes

UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) is a enzyme involved in the biosynthesis of N-acetylglucosamine (O-GlcNAc), a key step in the glycosylation of proteins. O-GlcNAc Transferase is a protein that catalyzes the transfer of the O-GlcNAc unit from the substrate acetyl-CoA to the alpha-glucosidic acceptor N-acetylglucosamine. This enzyme is a key player in the regulation of protein glycosylation and is involved in a wide range of cellular processes, including cell signaling, tissue repair, and inflammation.

The O-GlcNAc Transferase enzyme is a member of the N-acetylglucosamine synthase family, which includes several different enzymes involved in the biosynthesis of O-GlcNAc. These enzymes share a common catalytic core and share a conserved active site, which allows them to coordinate with similar substrate molecules.

One of the unique features of O-GlcNAc Transferase is its specificity for the acceptor N-acetylglucosamine. This is achieved through the unique conformation of the enzyme, which allows it to recognize and bind to the N-acetylglucosamine molecule with high affinity. This specificity is important for the efficient regulation of protein glycosylation and for the proper functioning of cellular processes that rely on protein glycosylation.

In addition to its role in protein glycosylation, O-GlcNAc Transferase is also involved in the regulation of cellular processes that are not directly related to protein biosynthesis. For example, this enzyme has been shown to play a role in the regulation of cell migration and the assembly of tissues, such as muscle and brain cells.

The potential therapeutic applications of O-GlcNAc Transferase are vast and span a range of therapeutic areas. For example, inhibition of this enzyme has been shown to be a potential therapeutic approach for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, the regulation of O-GlcNAc Transferase has been implicated in a number of diseases, including diabetes, cardiovascular disease, and neuroinflammation.

In conclusion, UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) is a protein that plays a critical role in the regulation of protein biosynthesis and is involved in a wide range of cellular processes. The inhibition of this enzyme has the potential to be a therapeutic approach for a variety of diseases. Further research is needed to fully understand the role of O-GlcNAc Transferase in cellular processes and to develop effective therapies based on this protein.

Protein Name: UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase)

The "UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UDP-N-Acetylglucosamine--Peptide N-Acetylglucosaminyltransferase (O-GlcNAc Transferase) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets